AstraZeneca Selects the Brightinsight Platform to Build and Manage Its Digital Health Solutions Within a Regulatory-Compliant Environment
BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced a global digital health partnership with global biopharmaceutical leader, AstraZeneca. AstraZeneca selected the regulated BrightInsight Platform for its growing portfolio of digital health products and services.
Built under a robust Quality Management System to support regulated use cases, the BrightInsight Platform enables its biopharma and medtech customers to develop and host digital health devices, apps, algorithms and Software as a Medical Device (SaMD) at scale while maintaining compliance with privacy, security and regulatory requirements across the globe.
Recommended AI News: Three Secrets To Better Understanding Target Accounts And Buying Committees
“From our code to culture, BrightInsight is committed to supporting regulated digital health solutions across therapeutic areas, and we are honored to be selected by AstraZeneca to be its global digital health partner,” said Kal Patel, MD, CEO & Co-Founder, BrightInsight. “This partnership is an additional validation point that forward-thinking therapeutics companies like AstraZeneca see the value in leveraging the BrightInsight Platform, a scalable regulated IoT platform specifically designed for biopharma and medtech.”
AstraZeneca will develop apps, algorithms, Software as a Medical Device and connected devices on top of the BrightInsight Platform that enhance and personalize care while making overall healthcare delivery more efficient for patients and providers. The first major program the companies are collaborating on is in the chronic disease management space.
Recommended AI News: Security And Risk Management Trends For 2020
“We quickly dismissed the concept of building our own custom platform so we could focus instead on developing transformational digital health solutions that bring to the forefront our deep-rooted history in science and focus on driving patient outcomes,” said Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca. “We selected BrightInsight because its pre-built, compliant platform accelerates our time to market while allowing us to focus on digital health innovation and leveraging our clinical know-how to improve patient outcomes instead of the underlying infrastructure.”
Recommended AI News: 5 Technical Things you Should Know about Regression Testing and Retesting
Comments are closed, but trackbacks and pingbacks are open.